Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| R01DK051081 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institutes of Health (NIH) | NIH |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a three month comparison trial of standard dose parathyroid hormone (PTH) (1-34) and two different doses of Parathyroid Hormone-related Protein (PTHrP) (1-36). The investigators want to to demonstrate that daily subcutaneous injection of PTHrP (1-36) in postmenopausal women with osteoporosis stimulates bone formation to the same or greater degree than PTH (1-34) but with less bone resorption.
Osteoporosis is a metabolic bone disease characterized by low bone mass and structural deterioration of bone tissue. It results from failure of osteoblasts to form sufficient new bone, from an excessive rate of osteoclastic bone resorption, or from the combination of both processes. The resultant bone fragility leads to an increased susceptibility to fractures, especially of the hip, spine and wrist. There is an increased mortality rate following both hip and vertebral fractures, and the presence of one fracture is a potent risk factor for future fractures. This leads to a decline in the quality of life and an associated loss of independence among the millions of individuals in the United States and worldwide afflicted with the disease. There is an additional population at an increased risk for fractures due to a less severe loss of bone mass, known as osteopenia (1). Already ten million individuals in the United States are estimated to have the disease and thirty four million more are at increased risk due to low bone mass (1).
Approved pharmacological treatments for postmenopausal osteoporosis include two classes of drugs: the antiresorptive and the anabolics (2). The antiresorptive include estrogen, calcitonin, selective estrogen receptor modulators, and bisphosphonates. The antiresorptive medications prevent bone loss by inhibiting both osteoclastic bone resorption and formation, by slowing bone turnover, and by allowing for increased mineralization of osteoid (2). The increase in bone mineral density from the antiresorptive agents is generally reported to be in the range of 2-8% over 1-7 years (3-7).
There is only one anabolic agent that is presently approved by the FDA for treatment for osteoporosis: parathyroid hormone, PTH (1-34), or teriparatide. PTH(1-34) was approved by the FDA in 2002 and it acts by increasing bone density by stimulating the PTH-1 receptor. This induces an increase in osteoblast mediated bone formation and osteoclast mediated bone resorption. Daily subcutaneous PTH is anabolic as there is stimulation of bone formation to a greater extent than bone resorption. The overall net result of biosynthetic PTH (1-34) is an increase in bone mineral density and a decrease in fractures (8). Daily PTH(1-34) treatment has been shown to effectively reduce the risk of both vertebral and nonvertebral fractures. Measurements of bone mineral density (BMD) of the lumbar spine (LS) resulted in an increase in bone density of 9 percent when compared to placebo (9). A daily 20 microgram dose of subcutaneous PTH(1-34) reduced the risk of getting two or more vertebral fractures by 77%, and the risk of at least one moderate or severe fracture was reduced by 90 and 78% respectively (9). Additionally, one vertebral fracture was prevented for every 12 patient years of treatment, and women were 35% less likely to have one or more new nonvertebral fragility fractures (9).
Parathyroid hormone-related protein or PTHrP is a protein peptide that was first isolated in 1987 as the factor responsible for the syndrome of humoral hypercalcemia of malignancy (HHM) (10-14). PTHrP is found in almost every tissue and cell type in the body, and appears to regulate cellular proliferation, survival, and differentiation in normal tissue as well as in malignancies (15-16). As the name implies, PTHrP is similar to PTH. Both peptides bind to the same receptor, PTH-1 R, and activate downstream signaling pathways causing similar post receptor effects (17).
Since PTH is a potent anabolic agent, we hypothesize that PTHrP may act in an anabolic fashion as well. We are seeking to demonstrate in this study that PTHrP acts as an anabolic agent in the treatment of osteoporosis with similar or better efficacy than PTH in respect to bone formation but with less bone resorption and fewer side effects, such as hypercalcemia.
The current studies are a sequel to initial phase 1 trials assessing the efficacy and safety of daily subcutaneous injection of PTHrP on the human skeleton. Previous studies have demonstrated that a single daily injection of ~ 400 mcg/day of PTHrP (1-36) in postmenopausal women on estrogen with osteoporosis led to a 4.7% increase in lumbar spine bone mineral density (BMD) after three months and all subjects were free of hypercalcemia or other adverse effects (18). In contrast with PTH, the doses of PTHrP are much larger, yet well-tolerated, and the increments in spine BMD are large and rapid with some subjects showing increases in spine BMD of 6-8% in as soon as three months in studies done thus far (18). PTHrP appears to selectively stimulate bone formation without stimulating bone resorption (18). This exciting observation may point towards PTHrP being a pure skeletal anabolic agent (21). Preliminary data analysis from a more recent three week dose escalation trial indicates demonstrates that the dose of 500 mcg/day of PTHrP causes 38% increase in P1NP and a 20% decrease in CTX indicating far greater bone formation than bone resorption with no hypercalcemia. At 625 mcg/day there were similar increases in P1NP with hypercalcemia in only 10% of subjects and hypercalcuria in 20%. In contrast in subjects receiving 750 mcg/day 50% developed hypercalcemia requiring early termination. The P1NP and CTX data from the three week dose escalation trial was used for both determining dose and sample size calculations for this study.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| PTHrP 400 mcg/day | Experimental | Post-menopausal women with osteoporosis will subcutaneously administer PTHrP 400 micrograms daily for three months. |
|
| PTHrP 600 mcg/day | Experimental | Post-menopausal women with osteoporosis will subcutaneously administer PTHrP 600 micrograms daily for three months. |
|
| PTH 20 mcg/day | Active Comparator | Post-menopausal women with osteoporosis will subcutaneously administer the FDA approved dose of PTH 20 micrograms daily for three months. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Parathyroid hormone related protein (1-36) | Drug | PTHrP (1-36) 400 micrograms / day administered subcutaneously for 3 months |
|
| Measure | Description | Time Frame |
|---|---|---|
| Procallagen-1 Amino-terminal Peptide (P1NP) | Baseline, Day 15, Day 30, Day 60, Day 90 | |
| Carboxy-terminal Telopeptides of Collagen-1 (CTX) | Baseline, Day 15, Day 30, Day 60, Day 90 |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in Bone Mineral Density of the Lumbar Spine. | 90 days | |
| Changes in Bone Mineral Density of the Total Hip. | 90 days | |
| Changes in Bone Mineral Density of the Femoral Neck. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Mara J Horwitz, MD | University of Pittsburgh | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UPMC Clinical & Translational Research Center | Pittsburgh | Pennsylvania | 15213 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| Background | http://www.nof.org/osteoporosis/diseasefacts.htm. Accessed August 22, 2008 | ||
| 18349061 | Background | Black DM, Bouxsein ML, Palermo L, McGowan JA, Newitt DC, Rosen E, Majumdar S, Rosen CJ; PTH Once-Weekly Research (POWR) Group. Randomized trial of once-weekly parathyroid hormone (1-84) on bone mineral density and remodeling. J Clin Endocrinol Metab. 2008 Jun;93(6):2166-72. doi: 10.1210/jc.2007-2781. Epub 2008 Mar 18. | |
| 8892713 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | PTHrP 400 mcg/Day | Post-menopausal women with osteoporosis or low bone density will subcutaneously administer Parathyroid hormone related protein (PTHrP) 1-36, 400 micrograms / day for 3 months |
| FG001 | PTHrP 600 mcg/Day | Post-menopausal women with osteoporosis or low bone density will subcutaneously administer Parathyroid hormone related protein (PTHrP) 1-36, 600 micrograms / day for 3 months |
| FG002 | PTH 20 mcg/Day | Post-menopausal women with osteoporosis or low bone density will subcutaneously administer Parathyroid hormone (PTH) 1-34, 20 micrograms / day for 3 months |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Postmenopausal women age 45-75 with osteoporosis or low bone density
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | PTHrP 400 mcg/Day | Post-menopausal women with osteoporosis or low bone density will subcutaneously administer Parathyroid hormone related protein (PTHrP) 1-36, 400 micrograms / day for 3 months |
| BG001 | PTHrP 600 mcg/Day |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Procallagen-1 Amino-terminal Peptide (P1NP) | Posted | Mean | Standard Error | percentage change from baseline | Baseline, Day 15, Day 30, Day 60, Day 90 |
|
Not provided
Adverse event data was collected at each study visit.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | PTHrP 400 mcg/Day | Post-menopausal women with osteoporosis will subcutaneously administer PTHrP 400 micrograms daily for three months. |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Dermatologic | Skin and subcutaneous tissue disorders | Systematic Assessment |
This study was not double-blinded. There was no placebo group in this study. Subjects had higher than anticipated calcium intake and baseline vitamin D levels.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Mara J Horwitz | UPittsburgh | 4126922848 | horwitz@pitt.edu |
Not provided
| ID | Term |
|---|---|
| D010024 | Osteoporosis |
| ID | Term |
|---|---|
| D001851 | Bone Diseases, Metabolic |
| D001847 | Bone Diseases |
| D009140 | Musculoskeletal Diseases |
| D008659 | Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C079957 | parathyroid hormone-related peptide (1-36) |
| D044162 | Parathyroid Hormone-Related Protein |
| D010281 | Parathyroid Hormone |
| D019379 | Teriparatide |
| ID | Term |
|---|---|
| D036361 | Peptide Hormones |
| D006728 | Hormones |
| D006730 | Hormones, Hormone Substitutes, and Hormone Antagonists |
| D036341 | Intercellular Signaling Peptides and Proteins |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Parathyroid hormone related protein(1-36) | Drug | PTHrP(1-36)600 micrograms subcutaneously administered daily for 3 months |
|
|
| Parathyroid hormone (1-34) | Drug | PTH(1-34)20 micrograms subcutaneously administered daily for 3 months |
|
|
| 90 days |
| Changes in Bone Mineral Density of the Forearm. | 90 days |
| Changes in Bone Mineral Density of the Distal 1/3 Radius. | 90 days |
| Total Serum Calcium (mg/dl) | Baseline, Day 15, Day 30, Day 60, Day 90 |
| Serum Phosphorous | Baseline, Day 15, Day 30, Day 60, Day 90 |
| 24 Hour Urine Calcium | 90 days |
| 1,25 Vitamin D | Baseline, Day 15, Day 30, Day 60, Day 90 |
| Fractional Excretion of Calcium | (Serum Creatinine X Urine Calcium)/(Serum Calcium X Urine Creatinine) | Baseline, Day 15, Day 30, Day 60, Day 90 |
| Tubular Maximum for Phosphorous/Glomerular Filtration Rate (TMP/GFR) | Fractional tubular reabsorption of phosphate (TRP) = 1-{(U phos/P phos) x ( P creat/U creat)} if TRP < or = 0.86 then TMP/GFR = TRP x P phos if TRP > 0.86 then TMP/GFR = 0.3 x TRP/{1-(0.8 x TRP)} x P phos U= urine, P = plasma | Baseline, Day 15, Day 30, Day 60, Day 90 |
| Background |
| Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI. JAMA. 1996 Nov 6;276(17):1389-96. |
| 7477143 | Background | Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995 Nov 30;333(22):1437-43. doi: 10.1056/NEJM199511303332201. |
| 9385122 | Background | Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 1997 Dec 4;337(23):1641-7. doi: 10.1056/NEJM199712043372301. |
| 10996576 | Background | Chesnut CH 3rd, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med. 2000 Sep;109(4):267-76. doi: 10.1016/s0002-9343(00)00490-3. |
| 10843171 | Background | Fogelman I, Ribot C, Smith R, Ethgen D, Sod E, Reginster JY. Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group. J Clin Endocrinol Metab. 2000 May;85(5):1895-900. doi: 10.1210/jcem.85.5.6603. |
| 11346808 | Background | Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001 May 10;344(19):1434-41. doi: 10.1056/NEJM200105103441904. |
| 6253785 | Background | Stewart AF, Horst R, Deftos LJ, Cadman EC, Lang R, Broadus AE. Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and nonhumoral groups. N Engl J Med. 1980 Dec 11;303(24):1377-83. doi: 10.1056/NEJM198012113032401. |
| 7085851 | Background | Stewart AF, Vignery A, Silverglate A, Ravin ND, LiVolsi V, Broadus AE, Baron R. Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: uncoupling of bone cell activity. J Clin Endocrinol Metab. 1982 Aug;55(2):219-27. doi: 10.1210/jcem-55-2-219. |
| 10639544 | Background | Strewler GJ. The physiology of parathyroid hormone-related protein. N Engl J Med. 2000 Jan 20;342(3):177-85. doi: 10.1056/NEJM200001203420306. No abstract available. |
| 3043221 | Background | Broadus AE, Mangin M, Ikeda K, Insogna KL, Weir EC, Burtis WJ, Stewart AF. Humoral hypercalcemia of cancer. Identification of a novel parathyroid hormone-like peptide. N Engl J Med. 1988 Sep 1;319(9):556-63. doi: 10.1056/NEJM198809013190906. No abstract available. |
| 8592727 | Background | Philbrick WM, Wysolmerski JJ, Galbraith S, Holt E, Orloff JJ, Yang KH, Vasavada RC, Weir EC, Broadus AE, Stewart AF. Defining the roles of parathyroid hormone-related protein in normal physiology. Physiol Rev. 1996 Jan;76(1):127-73. doi: 10.1152/physrev.1996.76.1.127. |
| 8156938 | Background | Orloff JJ, Reddy D, de Papp AE, Yang KH, Soifer NE, Stewart AF. Parathyroid hormone-related protein as a prohormone: posttranslational processing and receptor interactions. Endocr Rev. 1994 Feb;15(1):40-60. doi: 10.1210/edrv-15-1-40. |
| 12679445 | Background | Horwitz MJ, Tedesco MB, Sereika SM, Hollis BW, Garcia-Ocana A, Stewart AF. Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1-36) [hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers. J Clin Endocrinol Metab. 2003 Apr;88(4):1603-9. doi: 10.1210/jc.2002-020773. |
| 12574182 | Background | Horwitz MJ, Tedesco MB, Gundberg C, Garcia-Ocana A, Stewart AF. Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab. 2003 Feb;88(2):569-75. doi: 10.1210/jc.2002-021122. |
| 10934650 | Background | Stewart AF, Cain RL, Burr DB, Jacob D, Turner CH, Hock JM. Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathyroid hormone 1-34, parathyroid hormone-related protein 1-36, and SDZ-parathyroid hormone 893. J Bone Miner Res. 2000 Aug;15(8):1517-25. doi: 10.1359/jbmr.2000.15.8.1517. |
| 17872377 | Background | Dean T, Vilardaga JP, Potts JT Jr, Gardella TJ. Altered selectivity of parathyroid hormone (PTH) and PTH-related protein (PTHrP) for distinct conformations of the PTH/PTHrP receptor. Mol Endocrinol. 2008 Jan;22(1):156-66. doi: 10.1210/me.2007-0274. Epub 2007 Sep 13. |
| 15265822 | Background | Bisello A, Horwitz MJ, Stewart AF. Parathyroid hormone-related protein: an essential physiological regulator of adult bone mass. Endocrinology. 2004 Aug;145(8):3551-3. doi: 10.1210/en.2004-0509. No abstract available. |
| 16151606 | Background | Horwitz MJ, Tedesco MB, Sereika SM, Garcia-Ocana A, Bisello A, Hollis BW, Gundberg C, Stewart AF. Safety and tolerability of subcutaneous PTHrP(1-36) in healthy human volunteers: a dose escalation study. Osteoporos Int. 2006 Feb;17(2):225-30. doi: 10.1007/s00198-005-1976-3. Epub 2005 Sep 7. |
| Background | FORTEO (package insert). Indianapolis, IN: Eli Lilly and Company; 2008. |
| 17609307 | Background | Miller PD, Bilezikian JP, Diaz-Curiel M, Chen P, Marin F, Krege JH, Wong M, Marcus R. Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide. J Clin Endocrinol Metab. 2007 Sep;92(9):3535-41. doi: 10.1210/jc.2006-2439. Epub 2007 Jul 3. |
| 16087825 | Background | McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, Donley DW, Dalsky GP, Eriksen EF. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med. 2005 Aug 8-22;165(15):1762-8. doi: 10.1001/archinte.165.15.1762. |
| 18422590 | Background | Anastasilakis AD, Goulis DG, Polyzos SA, Gerou S, Koukoulis GN, Efstathiadou Z, Kita M, Avramidis A. Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial. Int J Clin Pract. 2008 Jun;62(6):919-24. doi: 10.1111/j.1742-1241.2008.01768.x. Epub 2008 Apr 17. |
| 16491282 | Background | Tashjian AH Jr, Gagel RF. Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis. J Bone Miner Res. 2006 Mar;21(3):354-65. doi: 10.1359/JBMR.051023. Epub 2005 Nov 11. No abstract available. |
| Background | Horwitz MJ, Stewart Af. Humoral hypercalcemia of malignancy. In: Favus MF (ed.) Primer on Metabolic Bone Diseases and Disorders of Mineral Metabolism, 5th ed. American Society for Bone and Mineral Research, Washington, DC, USA, pp. 246-250:2003. |
| 7273794 | Background | Lachin JM. Introduction to sample size determination and power analysis for clinical trials. Control Clin Trials. 1981 Jun;2(2):93-113. doi: 10.1016/0197-2456(81)90001-5. |
| Protocol Violation |
|
Post-menopausal women with osteoporosis or low bone density will subcutaneously administer Parathyroid hormone related protein (PTHrP) 1-36, 600 micrograms / day for 3 months
| BG002 | PTH 20 mcg/Day | Post-menopausal women with osteoporosis or low bone density will subcutaneously administer Parathyroid hormone (PTH) 1-34, 20 micrograms / day for 3 months |
| BG003 | Total | Total of all reporting groups |
| Participants |
|
| Age, Continuous | Mean | Standard Deviation | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
Post-menopausal women with osteoporosis or low bone density will subcutaneously administer Parathyroid hormone (PTH) 1-34, 20 micrograms / day for 3 months |
|
|
|
| Secondary | Changes in Bone Mineral Density of the Lumbar Spine. | Posted | Mean | Standard Error | Percent change from baseline | 90 days |
|
|
|
|
| Primary | Carboxy-terminal Telopeptides of Collagen-1 (CTX) | Posted | Mean | Standard Error | percentage change from baseline | Baseline, Day 15, Day 30, Day 60, Day 90 |
|
|
|
|
| Secondary | Changes in Bone Mineral Density of the Total Hip. | Posted | Mean | Standard Error | Percent change from baseline | 90 days |
|
|
|
|
| Secondary | Changes in Bone Mineral Density of the Femoral Neck. | Posted | Mean | Standard Error | Percent change from baseline | 90 days |
|
|
|
|
| Secondary | Changes in Bone Mineral Density of the Forearm. | Posted | Mean | Standard Error | Percent change from baseline | 90 days |
|
|
|
|
| Secondary | Changes in Bone Mineral Density of the Distal 1/3 Radius. | Posted | Mean | Standard Error | Percent change from baseline | 90 days |
|
|
|
|
| Secondary | Total Serum Calcium (mg/dl) | Posted | Mean | Standard Error | mg/dl | Baseline, Day 15, Day 30, Day 60, Day 90 |
|
|
|
|
| Secondary | Serum Phosphorous | Posted | Mean | Standard Error | mg/dl | Baseline, Day 15, Day 30, Day 60, Day 90 |
|
|
|
|
| Secondary | 24 Hour Urine Calcium | Posted | Mean | Standard Error | mg/gm creatinine | 90 days |
|
|
|
|
| Secondary | 1,25 Vitamin D | Posted | Mean | Standard Error | pg/ml | Baseline, Day 15, Day 30, Day 60, Day 90 |
|
|
|
|
| Secondary | Fractional Excretion of Calcium | (Serum Creatinine X Urine Calcium)/(Serum Calcium X Urine Creatinine) | Posted | Mean | Standard Error | % excreted | Baseline, Day 15, Day 30, Day 60, Day 90 |
|
|
|
|
| Secondary | Tubular Maximum for Phosphorous/Glomerular Filtration Rate (TMP/GFR) | Fractional tubular reabsorption of phosphate (TRP) = 1-{(U phos/P phos) x ( P creat/U creat)} if TRP < or = 0.86 then TMP/GFR = TRP x P phos if TRP > 0.86 then TMP/GFR = 0.3 x TRP/{1-(0.8 x TRP)} x P phos U= urine, P = plasma | Posted | Mean | Standard Error | mg/dl | Baseline, Day 15, Day 30, Day 60, Day 90 |
|
|
|
|
| 0 |
| 35 |
| 33 |
| 35 |
| EG001 | PTHrP 600 mcg/Day | Post-menopausal women with osteoporosis will subcutaneously administer PTHrP 600 micrograms daily for three months. | 0 | 35 | 31 | 35 |
| EG002 | PTH 20 mcg/Day | Post-menopausal women with osteoporosis will subcutaneously administer the FDA approved dose of PTH 20 micrograms daily for three months. | 0 | 35 | 27 | 35 |
| Musculoskeletal | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Neurologic | Nervous system disorders | Systematic Assessment |
|
| Psychological | Psychiatric disorders | Systematic Assessment |
|
| Gastrointestinal | Gastrointestinal disorders | Systematic Assessment |
|
| Infection | Infections and infestations | Systematic Assessment |
|
| Cardiovascular | Cardiac disorders | Systematic Assessment |
|
| Genitourinary | Renal and urinary disorders | Systematic Assessment |
|
| Other | General disorders | Systematic Assessment |
|
Not provided
Not provided
| D009750 |
| Nutritional and Metabolic Diseases |
| D010455 | Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |
| D011506 | Proteins |
| D001685 | Biological Factors |
|
| Day 60 |
|
| Day 90 |
|
|
| Day 30 |
|
| Day 60 |
|
| Day 90, time 0 |
|
| Day 90, time 3 hours |
|
| day 90, time 6 hours |
|
|
| Day 30 |
|
| Day 60 |
|
| Day 90 |
|
| Kruskal-Wallis | The threshold for statistical significance was p=0.05 | <0.005 | The reported p-value corresponds to the PTH group on Day 30 compared to the PTHrP 400 group and Day 60 compared to the PTHRp 600 group | 2-Sided | Yes | Non-Inferiority or Equivalence | Power calculations for this study were determined considering the expected effects of PTHrP (1-36) relative to PTH (1-34) on the primary endpoints of P1NP and CTX after 3 months of treatment relative to baseline using previously published data as weel as anticipated attrition rate. See primary outcomes. |
| Kruskal-Wallis | The threshold for statistical significance was p=0.05 | <0.0005 | The reported p-value correspond to the PTH group on Day 15 compared to the PTHrP 400 group and Day 15 and 30 compared to the PTHrP 600 group. | 2-Sided | Yes | Non-Inferiority or Equivalence | Power calculations for this study were determined considering the expected effects of PTHrP (1-36) relative to PTH (1-34) on the primary endpoints of P1NP and CTX after 3 months of treatment relative to baseline using previously published data as weel as anticipated attrition rate. See primary outcomes. |
|
|
| Day 30 |
|
| Day 60 |
|
| Day 90 |
|
| Kruskal-Wallis | The threshold for statistical significance was p=0.05 | <0.005 | The reported p-value corresponds to the comparison of the PTHrP 400 group at Day 15 to the PTHrP 600 and PTH groups | 2-Sided | Yes | Non-Inferiority or Equivalence | Power calculations for this study were determined considering the expected effects of PTHrP (1-36) relative to PTH (1-34) on the primary endpoints of P1NP and CTX after 3 months of treatment relative to baseline using previously published data as weel as anticipated attrition rate. See primary outcomes |
|
| Day 30 |
|
| Day 60 |
|
| Day 90 |
|
| Kruskal-Wallis | the threshold for statistical significance was p=0.05 | <0.005 | the reported p-value corresponds to change from baseline in the PTHrP 400 group at Day 15,30, 60 and 90 and the PTH group at day 90. | 2-Sided | Yes | Non-Inferiority or Equivalence | Power calculations for this study were determined considering the expected effects of PTHrP (1-36) relative to PTH (1-34) on the primary endpoints of P1NP and CTX after 3 months of treatment relative to baseline using previously published data as weel as anticipated attrition rate. |
|
| Day 30 |
|
| Day 60 |
|
| Day 90 |
|
| Kruskal-Wallis | the threshold for statistical significance was p=0.05 | <0.0005 | Thre reported p-value correspond to the PTH group compared to the PTHrp 600 group at day 15 | 2-Sided | Yes | Non-Inferiority or Equivalence | Power calculations for this study were determined considering the expected effects of PTHrP (1-36) relative to PTH (1-34) on the primary endpoints of P1NP and CTX after 3 months of treatment relative to baseline using previously published data as weel as anticipated attrition rate. |